Mechanism of Action
Naltrexone is a competitive opioid antagonist with the highest affinity for μ-opioid receptors. It functions by blocking the euphoric and analgesic effects of opioids through competitive receptor antagonism.
For alcohol use disorder, naltrexone reduces craving via modulation of the endogenous opioid system, which plays a key role in the rewarding effects of alcohol consumption.
- No abuse potential — not a controlled substance
- No opioid dependence develops from naltrexone itself
- Non-addictive pharmacological profile
- No euphoric or reinforcing properties
Pharmacokinetics Comparison
| Feature | Oral Naltrexone | XR Naltrexone (Vivitrol) |
|---|---|---|
| Dose | 50 mg/day | 380 mg IM monthly |
| Bioavailability | ~5-12% (extensive first-pass) | ~100% (bypasses first-pass) |
| Peak concentration | 1-2 hours | Day 2-3, sustained 30 days |
| Half-life | 4h (naltrexone), 13h (6-β-naltrexol) | Effective for 30+ days |
| Active metabolite | 6-β-naltrexol | Same |
| Metabolism | Hepatic | Same |
| Opioid blockade guarantee | No — patient-dependent | Yes — 30 days guaranteed |
| Adherence dependency | High | Eliminated post-injection |
XR Technology: PLG (poly-lactide-co-glycolide) microspheres release naltrexone gradually over 30 days as they biodegrade. This delivery system cannot be overridden by the patient, ensuring consistent therapeutic levels regardless of compliance behavior.
Indications: OUD vs AUD
Opioid Use Disorder (OUD)
XR naltrexone is strongly preferred for OUD treatment. Oral naltrexone is NOT recommended by ASAM for OUD due to catastrophic non-adherence combined with lost tolerance, which creates significant overdose risk.
- XR:BOT Trial: 28% failed XR initiation vs. 5% for buprenorphine
- Per-protocol analysis: Equivalent efficacy to buprenorphine when initiated successfully
- Adherence guarantee makes XR essential for OUD pharmacotherapy
Alcohol Use Disorder (AUD)
Oral naltrexone is evidence-based and appropriate for AUD. The NNT = 12 for preventing heavy drinking (COMBINE trial data). XR naltrexone is preferred when adherence is a clinical concern.
- Oral: First-line when adherence is adequate
- XR: Preferred when adherence concerns exist
- Both formulations equally effective if taken consistently
XR Naltrexone (Vivitrol) Key Features
- Guaranteed 30-day opioid blockade — patient cannot simply stop taking it
- Eliminates daily adherence problem entirely
- Injection site reactions in 8% (nodules, soreness, occasional induration)
- Cannot be reversed — must wait for clearance (~30 days)
- Ideal candidates: criminal justice populations, healthcare professionals with monitoring requirements, patients with strong anti-agonist preference
- Requires 7-10 opioid-free days before injection (the "initiation barrier")
- Alkermes STAR program: free drug assistance for uninsured patients
Oral Naltrexone Key Features
- Generic available: $3-15/month vs. $1,500-1,700/month for XR
- Patient controls adherence — both a limitation (for OUD) and an advantage (can stop if needed)
- Appropriate for AUD when adherence is adequate
- NOT recommended for OUD (ASAM guideline violation)
- Can stop immediately if emergency surgery or acute pain management needed
- Available at any pharmacy; no special ordering required
Head-to-Head Comparison Table
| Factor | Oral Naltrexone | XR Naltrexone |
|---|---|---|
| Cost | $3-15/month | ~$1,500-1,700/month |
| Insurance | Good (generic) | Medicaid varies; manufacturer PAP available |
| Administration | Daily pill | Monthly office injection |
| Confirmed adherence | No | Yes — 30 days |
| OUD recommendation | Not recommended (ASAM) | First-line when feasible |
| AUD recommendation | First-line (standard adherence) | Preferred (adherence concern) |
| Opioid-free requirement | 7-10 days | 7-10 days (same) |
| Reversibility | Stop next dose | Cannot reverse — wait 30 days |
| Emergency pain | Plan around next dose | Must use non-opioid alternatives |
| Injection site reactions | N/A | ~8% |
| Pregnancy | Limited data; caution | Not preferred |
| Hepatic safety | Monitor LFTs | Same |
The Initiation Barrier Problem
28% of OUD patients fail to start XR naltrexone (compared to only 5% for buprenorphine). The primary reason: inability to achieve the required 7-10 opioid-free days before injection.
Fentanyl complicates initiation due to its longer tissue half-life and lipophilicity, making the washout period more challenging than with heroin or prescription opioids.
Bridging Strategies
- Supervised inpatient/residential detox → immediate XR at discharge
- Outpatient clonidine + comfort medications → XR when opioid-free status confirmed via UDS
- Naloxone challenge before injection (verify opioid-free status)
- Criminal justice: controlled environment enables detox → XR at release
When XR is Preferred Despite the Barrier
- Patient refuses agonist therapy (buprenorphine/naltrexone)
- Criminal justice setting with supervision available
- Healthcare professional with monitoring requirements
- Strong patient preference for non-agonist approach
- Religious or philosophical objection to agonist therapy
Clinical Decision Algorithm
What is the primary diagnosis?
Pre-Treatment Checklist
Before Oral Naltrexone (AUD)
- Confirm AUD diagnosis per DSM-5 criteria
- LFTs (contraindicated if >3-5x ULN)
- Renal function assessment
- Pregnancy test when applicable
- Screen for opioid use (precipitated withdrawal risk)
- Patient education on daily adherence importance
Before XR Naltrexone (OUD — Additional Requirements)
- Confirm opioid-free ≥7-10 days (UDS negative)
- Consider naloxone challenge if uncertain
- Verify no opioid analgesics needed in next 30 days
- Injection site assessment (avoid areas with significant subcutaneous fat loss)
- Emergency pain management plan documented in chart
Absolute Contraindications (Both Formulations)
- Acute opioid dependence (risk of precipitated withdrawal)
- LFTs >3-5x ULN (hepatic safety concern)
- Known allergy to naltrexone or components
- Acute hepatitis or hepatic failure
Special Populations
Pregnancy
Limited data available; generally avoided. Buprenorphine preferred for OUD in pregnancy (better safety profile).
Hepatic Impairment
Monitor LFTs regularly. Use caution when >3x ULN. Avoid in acute hepatitis or hepatic failure.
Renal Impairment
Mild-moderate: no adjustment needed. Severe: use with caution (limited data).
Elderly Patients
Reduced clearance expected. Standard dosing with close monitoring for adverse effects.
Criminal Justice
XR highly effective in this population. Injection at release is ideal timing.
Adolescents (16-18)
Limited data; use with close monitoring. Consider risks/benefits carefully.
Cost & Adherence
Oral Cost-Effective When:
- AUD with good adherence track record
- Reliable pharmacy access
- XR cost prohibitive (uninsured without PAP)
XR Cost-Effective When:
- OUD treatment (adherence = survival)
- Documented oral non-adherence
- Criminal justice setting
- Medicaid coverage available
STAR Program
Alkermes patient assistance for uninsured patients — free drug available
1-800-VIVITROL
Emergency Pain Management
⚠️ Critical Considerations for XR Patients
For patients on XR naltrexone who need emergency pain management:
- Opioids will have REDUCED/NO effect for up to 30 days
- Document in chart: "Patient on XR naltrexone (Vivitrol) — opioid blockade active"
Preferred Alternatives
- Regional anesthesia (nerve blocks, spinal/epidural)
- Ketamine (NMDA antagonist, bypasses opioid receptors)
- NSAIDs and acetaminophen (multimodal approach)
- Non-opioid nerve blocks
If Opioids Absolutely Required
- MUCH higher doses needed due to receptor blockade
- Significant respiratory depression risk
- Anesthesia consultation strongly recommended
- Monitor in controlled setting (ICU/post-op)
Recommendations
- MedicAlert bracelet recommended for XR patients
- Plan elective surgery/procedures before next injection when possible
- Coordinate with anesthesiology for urgent cases
Clinical Pearls
"Don't prescribe oral naltrexone for OUD" — ASAM explicitly recommends against it due to adherence failure risk.
"XR works when you can get patients started" — equal to buprenorphine in per-protocol analysis.
"The opioid-free period is the bridge problem" — plan detox proactively, not reactively.
"Lost tolerance = overdose risk" — any gap in naltrexone for OUD is dangerous if relapse occurs.
"Have an emergency pain plan" — document in chart, recommend MedicAlert bracelet.
"For AUD, oral is fine if they take it" — effective; NNT=12 for heavy drinking.
"COMBINE trial: naltrexone + therapy > therapy alone for AUD"
"Naltrexone ≠ Narcan" — patient and family education essential to avoid confusion.
References
- Lee JD et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. NEJM 2018
- Anton RF et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. JAMA 2006
- ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. 2020 Edition
- Friedmann PD et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. NEJM 2012
- Vivitrol (naltrexone for extended-release injectable suspension) Prescribing Information. Alkermes, Inc.
- Rösner S et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010